Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Tonix Pharmaceuticals Holding / Equity Bottom-Up

<ul><li>Tonix Pharmaceuticals Holding Corp. (TNXP) recently announced certain preliminary financial information and selected preliminary operating results for the quarter ended June 30, 2025.</li><li>The company exited the second quarter of 2025 with approximately $125.3 million in cash and cash equivalents and subsequently raised an additional $50.6 million in July 2025, which is sufficient to fund operations into the third quarter of 2026.</li><li> This report also provides an in-depth look at TNX-1500, a third-generation anti-CD40 ligand (CD40L) antibody, as a therapy to prevent allograft and bone marrow transplant rejection and a treatment for autoimmune diseases.</li></ul>

Tonix Pharmaceuticals Holding Corp. (TNXP) recently announced certain preliminary financial information and selected preliminary operating results for the quarter ended June 30, 2025.The company exited the second quarter of 2025 with approximately $125.3 million in cash and cash equivalents and subsequently raised an additional $50.6 million in July 2025, which is sufficient to fund operations into the third quarter of 2026. This report also provides an in-depth look at TNX-1500, a third-generation anti-CD40 ligand (CD40L) antibody, as a therapy to prevent allograft and bone marrow transplant rejection and a treatment for autoimmune diseases.

TNXP: 2Q25 Financial Update and Deep Dive Into TNX-1500 